Supernus Pharmaceuticals (SUPN) EBT (2016 - 2025)
Historic EBT for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$58.0 million.
- Supernus Pharmaceuticals' EBT fell 22895.0% to -$58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.7 million, marking a year-over-year decrease of 12860.73%. This contributed to the annual value of $97.9 million for FY2024, which is 343448.9% up from last year.
- According to the latest figures from Q3 2025, Supernus Pharmaceuticals' EBT is -$58.0 million, which was down 22895.0% from $16.7 million recorded in Q2 2025.
- Supernus Pharmaceuticals' 5-year EBT high stood at $44.9 million for Q3 2024, and its period low was -$58.0 million during Q3 2025.
- For the 5-year period, Supernus Pharmaceuticals' EBT averaged around $9.9 million, with its median value being $10.9 million (2021).
- Its EBT has fluctuated over the past 5 years, first soared by 256484.85% in 2024, then plummeted by 249958.85% in 2025.
- Supernus Pharmaceuticals' EBT (Quarter) stood at $2.1 million in 2021, then skyrocketed by 1613.31% to $35.1 million in 2022, then crashed by 97.18% to $990000.0 in 2023, then surged by 2564.85% to $26.4 million in 2024, then tumbled by 319.67% to -$58.0 million in 2025.
- Its EBT was -$58.0 million in Q3 2025, compared to $16.7 million in Q2 2025 and -$5.8 million in Q1 2025.